MD Pediatrix Medical Group, Inc.
Services-Hospitals · NYSE · SEC CIK 893949 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.9%
TTM net income YoY-7.5%
TTM EPS YoY-4.2%
Revenue 3-yr CAGR-0.9%
Net income 3-yr CAGR17.1%
Margins
Gross margin—
Operating margin10.9%
Net margin7.7%
FCF margin—
EBITDA margin12.1%
Returns
ROE17.2%
ROA6.9%
ROIC (approx.)13.8%
Asset turnover0.90x
Leverage & solvency
Liabilities / assets60.3%
Debt / equity0.68x
Current ratio1.28x
Interest coverage6.38x
Cash quality & payout
Operating cash flow / net income1.51x
Accruals ratio-3.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $501.37M | $487.78M | $476.20M | $493.77M | $492.88M | $468.84M | $458.36M | $502.36M |
| SG&A expense | $62.70M | $61.29M | $60.27M | $65.68M | $60.79M | $55.71M | $58.60M | $63.55M |
| Operating income | $65.21M | $56.92M | $41.66M | $48.79M | $68.05M | $59.87M | $32.10M | $39.29M |
| Interest expense | $8.13M | $8.17M | $8.27M | $8.74M | $8.94M | $9.13M | $9.15M | $9.71M |
| Pretax income | $64.99M | $54.00M | $38.84M | $45.59M | $87.78M | $54.97M | $28.09M | $33.33M |
| Income tax | $18.00M | $14.16M | $9.27M | $11.91M | $16.07M | $15.71M | $7.35M | $2.85M |
| Net income | $46.99M | $39.84M | $29.57M | $33.68M | $71.71M | $39.26M | $20.74M | $30.48M |
| EBITDA | $71.45M | $62.70M | $47.78M | $54.42M | $73.60M | $65.18M | $37.43M | $46.16M |
| EPS (basic) | 0.61 | 0.50 | 0.37 | — | 0.85 | 0.46 | 0.25 | — |
| EPS (diluted) | 0.59 | 0.49 | 0.36 | — | 0.84 | 0.46 | 0.24 | — |
| Weighted avg. shares (diluted) | 79.73M | 81.41M | 83.08M | — | 85.61M | 85.53M | 85.43M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $311.92M | $288.88M | $205.78M | $375.24M | $340.06M | $224.73M | $98.98M | $229.94M |
| Short-term investments | $113.92M | $115.32M | $123.19M | $124.48M | $123.04M | $123.59M | $120.20M | $118.57M |
| Receivables | $231.82M | $227.60M | $224.80M | $229.66M | $231.12M | $238.99M | $242.53M | $259.99M |
| Current assets | $684.08M | $660.14M | $587.03M | $763.51M | $717.20M | $613.05M | $491.67M | $639.61M |
| PP&E, net | $37.24M | $38.70M | $41.09M | $39.18M | $38.64M | $38.94M | $38.22M | $39.17M |
| Goodwill | $1.27B | $1.27B | $1.27B | $1.26B | $1.26B | $1.24B | $1.24B | $1.24B |
| Intangibles | $13.10M | $14.51M | $15.94M | $16.86M | $14.80M | $9.30M | $10.39M | $11.60M |
| Total assets | $2.14B | $2.13B | $2.07B | $2.25B | $2.20B | $2.10B | $1.99B | $2.15B |
| Current liabilities | $535.73M | $501.58M | $442.64M | $458.91M | $392.55M | $341.04M | $271.05M | $434.11M |
| Short-term debt | $179.95M | $186.18M | $192.42M | $26.81M | $25.34M | $23.68M | $22.13M | $20.55M |
| Long-term debt | $397.77M | $398.06M | $398.35M | $570.53M | $577.17M | $583.86M | $590.48M | $597.12M |
| Total debt | $577.72M | $584.24M | $590.77M | $597.34M | $602.51M | $607.55M | $612.60M | $617.66M |
| Total liabilities | $1.29B | $1.25B | $1.19B | $1.38B | $1.31B | $1.27B | $1.20B | $1.39B |
| Shareholders' equity | $849.62M | $880.98M | $878.58M | $865.85M | $890.67M | $833.75M | $789.19M | $764.94M |
| Net debt | $265.80M | $295.36M | $384.99M | $222.10M | $262.45M | $382.82M | $513.63M | $387.72M |
| Shares outstanding | 78.09M | 81.22M | 82.06M | 82.98M | 85.83M | 86.85M | 85.81M | 85.87M |
| Cash flow statement | ||||||||
| Operating cash flow | $117.31M | $125.32M | -$129.85M | $114.10M | $137.28M | $137.17M | -$117.46M | $133.01M |
| Investing cash flow | -$4.64M | $6.02M | -$11.98M | -$10.28M | $6.60M | -$7.15M | -$7.46M | -$1.94M |
| Financing cash flow | -$89.63M | -$48.24M | -$27.64M | -$68.64M | -$28.56M | -$4.26M | -$6.04M | -$4.96M |
| Depreciation & amortization | $6.24M | $5.78M | $6.12M | $5.63M | $5.55M | $5.31M | $5.33M | $6.87M |
| Stock-based compensation | $6.20M | $5.08M | $4.66M | $5.34M | $3.40M | $2.00M | $3.64M | $2.74M |
| Share buybacks | $83.04M | $42.74M | $21.45M | $64.04M | $20.87M | $209,000 | $1.57M | $643,000 |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.